No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Analysts at JP Morgan raised their target price on drugmaker GSK to 22.50 on Monday on improving investor perception.
JP Morgan said after GSK's full-year earnings per share came in 2% ahead of consensus and its in-line FY26 constant currency guide, it had opted to trim 26/27E EPS by 1-2%.
The broker noted that GSK has rallied strongly off a low-PE post-results, and said it thinks this was due to continued operational delivery, as well as new chief executive Luke Miels' focus on accelerating R&D, low-risk BD and underwriting GSK's 40bn 31E revenue target and flat margins through dolutegravir LOE 28-31E.
"While we think more pipeline is needed to achieve the sales and margin targets we see momentum in R&D (7 PIII starts 25E, GSK flagging potential new pivotal trial starts 26/27E for its B7-H3 & B7-H4 ADCs, GSK'981 (KITi) for GIST, Cabenuva Q4M, LA TSLP and regimen selection for Q6M HIV to be announced at a June investor event)" said JPM.
"We see the stock as likely to hold these perception-shift gains but prefer not to chase hence raise our TP to 22.50 and maintain 'neutral'."
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.